LOMITAPIDE OPTIONS

Compound 60 has an exceedingly superior affinity to MDM2 (Ki < 1 nM), strong cellular exercise, and an excellent oral pharmacokinetic profile. Compound sixty is capable of achieving entire and very long-lasting tumor regression in vivo and is particularly currently in stage I scientific trials for most cancers therapy.BACKGROUNDDormant chemotherapy